Skip to main content
OpenTrials
Completed

NCT Number: NCT03832374

Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis

Rheumatoid arthritis is a genuine systemic disease associated with diffuse interstitial pneumopathy and bronchial disorders. According to the literature review, the prevalence of PID on thoracic CT scan is one-third of patients. Diffuse interstitial pneumopathy is responsible for a significant morbidity and mortality, is currently under-diagnosed and its treatment is poorly codified. The lung seems to have a central role in the genesis of rheumatoid arthritis. It also appears that some subtypes of anti citrullinated peptide antibodies are preferentially present in the lungs.

The hypothesis behind our project is that one or more subtypes of anti citrullinated peptide antibodies with a preferential tropism for the lung would attack the parenchyma and pulmonary airways.

Currently, there are no data on interstitial pneumopathy in black and Afro-Caribbean subjects with rheumatoid arthritis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Martinique

Fort-de-France, 97261, Martinique

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with rheumatoid arthritis ACR/EULAR 2010
  • Patient with a higher age or equal to 18
  • Patient receiving social security
  • Patient giving his free and informed written consent

Exclusion criteria

  • Patient with overlap syndrome with another autoimmune disease
  • Patients with known severe cardiopulmonary pathology
  • Woman who is pregnant and breast feeding
  • Patient with language difficulties or understanding

Treatment and study plan

descriptive

Other

Primary outcomes

  1. Frequency of the positivity of the anti citrullinated peptide antibodies and subtype

    Time frame: three years

    Presence of one or more subtypes of anti citrullinated peptide antibodies in the serum of patients with interstitial pneumopathy associated with rheumatoid arthritis who would be absent

Secondary outcomes

  1. Genetic analysis of the main mutations

    Time frame: three years

    Presence of mutation TERT, RTEL1, PARN et SFTPC

Sponsors and collaborators

Lead sponsor

University Hospital Center of Martinique

Other

Registry information

Official study title

Study of the Association Between Subtypes of Anti Citrullinated Peptide Antibodies and Lung Damage in Rheumatoid Arthritis in the West Indies

Acronym: ACPPPA

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Feb 6, 2019
Registry last updated
Mar 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.